Specific ceramide ratio and inflammation combine to signal risk
Written by Michela Luciano, PhD | July 30, 2026
- A specific blood ceramide ratio is linked to worsening cognitive decline in Parkinson's disease.
- Higher levels of this ratio predict poorer cognitive performance, partially mediated by inflammation.
- This blood marker could help identify Parkinson's patients at risk for thinking and memory problems.
Higher blood levels of a specific ratio between two fats, called ceramides, may help identify people with Parkinson’s disease who are more likely to develop thinking and memory problems, according to a new study.
A higher Cer 24:1/Cer 24:0 ratio was closely associated with worsening cognitive impairment and remained a strong independent predictor of poorer cognitive performance after accounting for other factors. Inflammation appeared to partially mediate this association, highlighting ceramide metabolism and inflammatory signaling as complementary biological features of cognitive impairment in Parkinson’s disease.
“These findings establish a ceramide-centered quantitative framework integrating metabolic and inflammatory dimensions of cognitive impairment in [Parkinson’s], supporting stratified biomarker development,” researchers wrote.
The study, “Plasma ceramide ratios define metabolic–inflammatory associations with cognitive impairment in Parkinson’s disease,” was published in npj Parkinson’s Disease.
Cognitive changes often detected after damage has occurred in brain
A progressive neurological disorder, Parkinson’s is most known for causing motor symptoms, but it can also affect thinking and memory. Cognitive impairment can range from mild difficulties with attention, planning, and language to dementia, which develops in up to 80% of people with Parkinson’s over the course of the disease.
These cognitive changes are often detected only after significant damage has already occurred in the brain, limiting opportunities for early intervention. This “diagnostic lag,” together with the wide variation in the progression of cognitive impairment from person to person, highlights the need for accessible biomarkers that reflect the biological processes underlying cognitive decline, according to researchers.
One group of promising candidates is ceramides, a family of fatty molecules that help maintain nerve cell membranes, regulate communication between nerve cells, and modulate inflammation. Previous studies have linked abnormal ceramide metabolism to Parkinson’s and faster cognitive decline.
However, the specific ceramide profiles associated with different stages of cognitive impairment remain unclear, as do their relationships with inflammation and biomarkers of neurodegeneration.
To address this gap, researchers in China analyzed blood samples from 408 people with Parkinson’s, 98 people with multiple system atrophy (MSA), a neurological disorder that shares many symptoms with Parkinson’s, and 220 healthy adults.
Recent Comments